Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $206.00 at Citigroup

Krystal Biotech (NASDAQ:KRYS) had its price objective raised by equities researchers at Citigroup from $204.00 to $206.00 in a report issued on Tuesday, Benzinga reports. The firm presently has a “neutral” rating on the stock. Citigroup’s price objective suggests a potential upside of 19.07% from the company’s previous close.

Several other brokerages have also issued reports on KRYS. Evercore ISI boosted their target price on Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research report on Monday, August 12th. Chardan Capital upped their price objective on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research report on Monday, August 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. HC Wainwright reissued a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research note on Tuesday. Finally, William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Krystal Biotech presently has a consensus rating of “Buy” and an average price target of $197.00.

Krystal Biotech Trading Up 1.3 %

Shares of KRYS stock traded up $2.16 on Tuesday, reaching $173.01. The company’s stock had a trading volume of 49,369 shares, compared to its average volume of 328,226. The stock’s fifty day simple moving average is $182.28 and its 200-day simple moving average is $180.12. Krystal Biotech has a 1 year low of $93.95 and a 1 year high of $219.34. The company has a market capitalization of $4.97 billion, a price-to-earnings ratio of 47.13 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.07. The firm had revenue of $83.84 million for the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a net margin of 63.73% and a return on equity of 1.99%. The business’s revenue was up 879.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.67) EPS. Equities research analysts forecast that Krystal Biotech will post 2.88 earnings per share for the current year.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the transaction, the insider now directly owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 14.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Krystal Biotech

Institutional investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD raised its stake in Krystal Biotech by 54.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock valued at $117,189,000 after purchasing an additional 231,255 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in Krystal Biotech by 1,972.0% during the 2nd quarter. Principal Financial Group Inc. now owns 123,469 shares of the company’s stock worth $22,674,000 after buying an additional 117,510 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Krystal Biotech by 115.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company’s stock worth $35,583,000 after purchasing an additional 103,928 shares in the last quarter. Capital World Investors purchased a new stake in shares of Krystal Biotech during the first quarter worth approximately $17,285,000. Finally, Public Sector Pension Investment Board acquired a new stake in shares of Krystal Biotech in the 2nd quarter valued at $10,037,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).